Lariago DS Tablet

Drug | Tablet

Treatment of malaria caused by chloroquine-sensitive Plasmodium species; treatment of extraintestinal amoebiasis (e.g., amoebic liver abscess) as an adjunct to tissue amoebicides

Chloroquine is an antimalarial that concentrates in parasite food vacuoles and inhibits heme polymerization, leading to toxic heme accumulation and parasite death. It also has anti-amoebic activity against certain forms of Entamoeba histolytica.

Take orally with food or milk to reduce stomach upset. Dose and duration depend on indication (malaria treatment/prophylaxis or amoebiasis) and must be as prescribed; swallow tablet with water and complete the full course.

Nausea, vomiting, abdominal pain, diarrhea, headache, dizziness, blurred vision, itching, rash

Use only for chloroquine-sensitive malaria; resistance is common in many regions. Use with caution in liver disease, kidney impairment, psoriasis, porphyria, G6PD deficiency, epilepsy, and cardiac disease. Risk of QT prolongation/arrhythmias, hypoglycaemia, blood disorders, and retinal toxicity with high doses or prolonged use—seek care for visual changes. Overdose can be fatal, especially in children; keep out of reach. Not for self-medication in malaria—confirm diagnosis and follow local guidelines.

QT-prolonging drugs (e.g., amiodarone, sotalol, macrolides, fluoroquinolones, antipsychotics), digoxin (may increase levels), antiepileptics (may reduce seizure control), cimetidine (may increase chloroquine levels), antacids/kaolin (reduce absorption—separate by 4 hours), insulin/antidiabetics (risk of hypoglycaemia), mefloquine (increased seizure/arrhythmia risk)